Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 539, P. 216745 - 216745
Published: May 1, 2025
Language: Английский
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 10, 2025
Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively identifies tumors metastatic lymph nodes for imaging purposes, while 177Lu-PSMA-617 (Pluvicto) has received FDA approval treating castration-resistant PCa (mCRPC). Despite their success, radionuclide-based diagnostic methods face limitations such as high costs side effects. Recently, near-infrared (NIR) fluorescence phototherapy advanced significantly biomedical applications. It's benefits, deep tissue penetration, real-time precision, minimal effects, driven broader adoption, especially fluorescence-guided surgery (FGS). This review suggests combining NIR dyes enable targeted, high-resolution superior signal-to-background ratios, facilitating precise FGS. techniques can also aid pathological diagnosis ex vivo specimens. Furthermore, photosensitizers allows localized photothermal (PTT) or photodynamic therapy (PDT) under irradiation, producing heat reactive oxygen species (ROS) treat PCa. aims extend the success of targeting by exploring advances NIR-based FGS phototherapy, presenting promising new approach.
Language: Английский
Citations
1
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 3, 2025
Targeting Prostate Specific Membrane Antigen (PSMA) has proven highly useful and beneficial for prostate cancer (PCa) theranostics. However, patients with advanced metastatic castration-resistant (mCRPC) lack optimal PSMA expression resulting in poor specificity. To address this limitation, combination targeting is gaining popularity by synergistically boosting the theranostic efficacy. Herein, we thoroughly reviewed most recent development of drug formulation PCa theranostics both Fibroblast Activation Protein (FAP). FAP known to overexpress cancer-associated fibroblasts (CAFs) within tumor microenvironment (TME). It been extensively studied as an effective target identification treatment a variety phenotypes. Along advantages current updates on FAP, Review discussed patterns various phenotypes, well their role growth, invasion, metastasis, which great interest design
Language: Английский
Citations
0
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 5, 2025
Despite its therapeutic potential, photodynamic therapy faces several key limitations in clinical applications, including poor drug delivery and insufficient tumor selectivity. We engineered RFYFYR-Ce6-RFYFYR (R-Ce6-R), a twin-tail peptide–photosensitizer conjugate that self-assembles into nanostructures for improved cancer treatment. By incorporating arginine-rich peptide sequences, this design not only enhances cellular internalization but also promotes peroxynitrite (ONOO–) formation, amplifying the effect. Our studies revealed R-Ce6-R achieves 33-fold higher potency than unmodified Ce6, with an IC50 of 0.18 μM. The demonstrated selective accumulation tissue, robust ROS generation, complete regression animal models while maintaining favorable safety profile. These results establish as innovative approach advancing
Language: Английский
Citations
0
Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 532, P. 216526 - 216526
Published: Feb. 21, 2025
Language: Английский
Citations
0
Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 534, P. 216587 - 216587
Published: March 14, 2025
Language: Английский
Citations
0
Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 539, P. 216745 - 216745
Published: May 1, 2025
Language: Английский
Citations
0